TABLE 1.
Bcc strains and mutants and plasmids used in this study
| Species or plasmid | Isolate | Descriptiona | Source | Reference |
|---|---|---|---|---|
| Species | ||||
| E. coli | DH5α | φ80lacZΔM15 ΔlacU169 endA1 recA1 hsdR17 supE44 thi-1 gyrA96 relA1 | ||
| B. cenocepacia | K56-2 (= LMG18863) | ET12, Toronto, Canada, CF | C. Mohr | 14 |
| J2315 (= LMG16656) | ET12 index strain, Edinburgh, UK, CF | J. Govan | 19 | |
| BC7 (= LMG18826) | ET12, Toronto, Canada, CF | BCCM/LMG | 64 | |
| J415 (= LMG16654) | Not associated with patient-to-patient spread, CF | BCCM/LMG | 18 | |
| K56-2 R2 | cepR mutant | P. Sokol | 39 | |
| K56-2 R2(pSLR100) | Complemented cepR mutant containing plasmid pSLR100 | P. Sokol | 39 | |
| B. stabilis | LMG14294 | Belgian CF patient, stable condition; detected in one other patient | BCCM/LMG | 58 |
| B. vietnamiensis | FC441 (= LMG18836) | 9-year-old boy with X-linked recessive CGD who survived septicemia | BCCM/LMG | 44 |
| B. cepacia | CEP509 (= LMG18821) | CF patient, Sydney, Australia; recovered from three other patients | BCCM/LMG | 44 |
| Plasmids | ||||
| pIN25 | oripBBR Δmob, Cmr, GFP | This study | ||
| pIN29 | oripBBR Δmob, Cmr, DSRed | This study | ||
| pIN62 | oripBBRmob+, Cmr, DSRed | This study | ||
| pIN63 | oripBBRmob+, Tpr, DSRed | This study | ||
| pIN72 | oripBBRmob+, Tetr, DSRed | This study |
a
CF, cystic fibrosis patient; CGD, chronic granulomatous disease; Cmr, chloramphenicol resistance; Tpr, trimethoprim resistance; Tetr, tetracycline resistance; Δmob, mobilization deficient.